Target Identification

Sub-optimal target selection is the primary driver of pipeline failure in immunology. MyImmune transforms this high-risk stage into a data-driven advantage. Our AI platform deciphers the complexity of the human immune system, translating millions of unique patient BCR/TCR sequences into generalizable, high-value therapeutic targets for autoimmune diseases and cancer.

We move beyond sequence similarity to map the functional epitope landscape. Our proprietary clustering algorithm identifies epitope-specific antibody groups with a demonstrated purity of 96%, providing validated, biologically relevant candidates directly from human immune responses. This precision ensures you pursue targets with the highest probability of success.

To further de-risk your discovery programs, we have created an integrated, best-in-class pipeline. MyImmune identifies potent, disease-specific antibodies, which are then analyzed by Acpharis's AI docking engine—the winner of the CASP-16 competition that outperformed AlphaFold 3. This synergy of immune decoding and world-class structural prediction delivers superior candidates, faster.

Increase the PTRS of your pipeline by building it on a foundation of validated human immunity.